FR0014000MR3 - Common Stock

Overall **ERF** gets a fundamental rating of **5** out of 10. We evaluated **ERF** against 16 industry peers in the **Life Sciences Tools & Services** industry. **ERF** has an average financial health and profitability rating. **ERF** has a decent growth rate and is not valued too expensively.

In the past year **ERF** was profitable.

In the past year **ERF** had a positive cash flow from operations.

Each year in the past 5 years **ERF** has been profitable.

With a **Return On Equity** value of **8.28%**, **ERF** is not doing good in the industry: **62.50%** of the companies in the same industry are doing better.

Measured over the past 3 years, the **Average Return On Invested Capital** for **ERF** is above the industry average of **9.31%**.

The 3 year average ROIC (**11.81%**) for **ERF** is well above the current ROIC(**7.41%**). The reason for the recent decline needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.01% | ||

ROE | 8.28% | ||

ROIC | 7.41% |

ROA(3y)6.56%

ROA(5y)4.79%

ROE(3y)13.98%

ROE(5y)10.73%

ROIC(3y)11.81%

ROIC(5y)9.71%

The **Operating Margin** of **ERF** (**12.77%**) is worse than **62.50%** of its industry peers.

In the last couple of years the **Operating Margin** of **ERF** has grown nicely.

In the last couple of years the **Gross Margin** of **ERF** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 12.77% | ||

PM (TTM) | 6.36% | ||

GM | 20.33% |

OM growth 3Y7.12%

OM growth 5Y2.81%

PM growth 3Y39.49%

PM growth 5Y7.46%

GM growth 3Y3.39%

GM growth 5Y3.77%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **ERF** is still creating some value.

The number of shares outstanding for **ERF** has been increased compared to 5 years ago.

The debt/assets ratio for **ERF** is higher compared to a year ago.

The **Debt to FCF ratio** of **ERF** (**8.90**) is better than **62.50%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.63 | ||

Debt/FCF | 8.9 | ||

Altman-Z | 2.78 |

ROIC/WACC0.95

WACC7.78%

A Current Ratio of **1.43** indicates that **ERF** should not have too much problems paying its short term obligations.

Looking at the **Current ratio**, with a value of **1.43**, **ERF** is doing worse than **81.25%** of the companies in the same industry.

A Quick Ratio of **1.35** indicates that **ERF** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.43 | ||

Quick Ratio | 1.35 |

The **Earnings Per Share** has been growing by **24.07%** on average over the past years. This is a very strong growth

The **Revenue** has been growing by **17.70%** on average over the past years. This is quite good.

EPS 1Y (TTM)-35%

EPS 3Y55.1%

EPS 5Y24.07%

EPS growth Q2Q-57.24%

Revenue 1Y (TTM)-5.06%

Revenue growth 3Y13.73%

Revenue growth 5Y17.7%

Revenue growth Q2Q-5.92%

Based on estimates for the next years, **ERF** will show a small growth in **Earnings Per Share**. The EPS will grow by **3.24%** on average per year.

Based on estimates for the next years, **ERF** will show a small growth in **Revenue**. The Revenue will grow by **5.31%** on average per year.

EPS Next Y-30.89%

EPS Next 2Y-9.31%

EPS Next 3Y-1.57%

EPS Next 5Y3.24%

Revenue Next Year-3.64%

Revenue Next 2Y1.6%

Revenue Next 3Y3.42%

Revenue Next 5Y5.31%

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

With a **Price/Earnings** ratio of **26.23**, **ERF** can be considered very expensive at the moment.

75.00% of the companies in the same industry are more expensive than **ERF**, based on the **Price/Earnings** ratio.

Based on the **Price/Forward Earnings** ratio of **18.44**, the valuation of **ERF** can be described as rather expensive.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **21.49**, **ERF** is valued at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 26.23 | ||

Fwd PE | 18.44 |

Based on the **Enterprise Value to EBITDA** ratio, **ERF** is valued cheaper than 93.75% of the companies in the same industry.

Based on the **Price/Free Cash Flow** ratio, **ERF** is valued cheaper than 93.75% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 28.5 | ||

EV/EBITDA | 10.21 |

PEG (NY)N/A

PEG (5Y)1.09

EPS Next 2Y-9.31%

EPS Next 3Y-1.57%

Compared to the average S&P500 **Dividend Yield** of **2.45**, **ERF** is paying slightly less dividend.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.74% |

The dividend of **ERF** is nicely growing with an annual growth rate of **48.35%**!

Dividend Growth(5Y)48.35%

Div Incr Years0

Div Non Decr Years0

DP46.58%

EPS Next 2Y-9.31%

EPS Next 3Y-1.57%

**EUROFINS SCIENTIFIC**

EPA:ERF (2/27/2024, 5:29:48 PM)

**54.56**

**-4.08 (-6.96%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap10.49B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.74% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 26.23 | ||

Fwd PE | 18.44 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)1.09

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.01% | ||

ROE | 8.28% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 12.77% | ||

PM (TTM) | 6.36% | ||

GM | 20.33% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.63

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.63 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.43 | ||

Quick Ratio | 1.35 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-35%

EPS 3Y55.1%

EPS 5Y

EPS growth Q2Q

EPS Next Y-30.89%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-5.06%

Revenue growth 3Y13.73%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y